NanoVibronix, Inc. specializes in the development of non-invasive therapeutic devices utilizing ultrasound technology, primarily targeting pain management and wound healing. The company operates in the U.S. and has a unique competitive advantage with its proprietary UltraSonic technology, which allows for drug-free pain relief and has applications in various medical fields.
Business Overview
NanoVibronix generates revenue through the sale of its medical devices, which are marketed directly to healthcare providers and patients. The company has a competitive edge due to its patented technology that offers drug-free treatment options, potentially reducing dependency on pharmaceuticals.
Regulatory approvals for new devices
Partnerships with healthcare providers
Market adoption rates of its products
Changes in reimbursement policies for medical devices
Risk Factors
Technological disruption from emerging therapies
Regulatory changes affecting device approvals
Increased competition from larger medical device manufacturers
Potential for new entrants with similar technologies
Liquidity risk due to negative cash flow
Limited financial resources for R&D and marketing
Macro Sensitivity
moderate - The demand for medical devices can be sensitive to economic cycles, as healthcare spending may decline in downturns.
Minimal impact as the company has low debt levels; however, higher rates could affect consumer spending on elective medical devices.
minimal - The company has a low debt/equity ratio, indicating limited reliance on credit.
Profile
growth - Investors looking for potential turnaround opportunities in the medical device sector.
high - The stock has shown significant volatility, with a 1-year return of -97.1%.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
